Kraft Heinz has launched a new Philadelphia plant-based cream cheese, which is gluten- and lactose-free and made without added flavors or dyes.
Robert Scott, Kraft Heinz’s president of research and development, noted that the influx of flexitarian consumers has driven growth within the plant-based market, which is now over 20 times the vegan population size.
He added that the brand’s current options for cream cheese standards weren’t meeting consumer expectations, and there was no trusted leader. Philadelphia plant-based spread not only provides a solution that mirrors the taste and texture of our iconic Philadelphia brand but also reinforces Kraft Heinz’s bet to bring plant-based offerings to the masses.
Philadelphia plant-based spread is sold at select retailers in Southeast US.
There would be additional flavors planned for the national rollout in summer 2023.


Gold Prices Fall as US-Iran Conflict, Rising Oil Prices Fuel Fed Rate Concerns
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast
AI is driving down the price of knowledge – universities have to rethink what they offer
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election
What’s the difference between baking powder and baking soda? It’s subtle, but significant
Why a ‘rip-off’ degree might be worth the money after all – research study
Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
US-Iran Strikes Escalate as Strait of Hormuz Crisis Pushes Oil Prices Higher
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates
Dollar Ends Week Higher as Yen Jumps on Japan Pension Fund Investment Plans
Dollar Slips as Oil Prices Ease, Fed Rate Outlook Remains Uncertain
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 



